Verastem, Inc.

Verastem, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Verastem, Inc. is not a good value stock. Verastem, Inc. is not very popular among insiders. Verastem, Inc. is a mediocre stock to choose.
Log in to see more information.
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developin...
VSTM Fundamental Data by TradingView

News

Contrasting Verastem (NASDAQ:VSTM) and Kaya (OTCMKTS:KAYS)
Contrasting Verastem (NASDAQ:VSTM) and Kaya (OTCMKTS:KAYS)

Zolmax Kaya (OTCMKTS:KAYS - Get Free Report) and Verastem (NASDAQ:VSTM - Get Free Report) are both small-cap consumer discretionary companies, but which is the better stock? We will contrast the two...\n more…

Verastem (NASDAQ:VSTM) versus Kaya (OTCMKTS:KAYS) Head to Head Review
Verastem (NASDAQ:VSTM) versus Kaya (OTCMKTS:KAYS) Head to Head Review

Ticker Report Verastem (NASDAQ:VSTM - Get Free Report) and Kaya (OTCMKTS:KAYS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based...\n more…

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Business Wire Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside...\n more…

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Business Wire Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the acceptance of a late-breaking abstract of the mature...\n more…

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity
Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Seeking Alpha - Long Ideas Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity...\n more…

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Business Wire Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first...\n more…